GET DAILY SIGNALSSutro Biopharma (STRO) Declines -32% Over 30 Days: Examining the Recent Selloff
Key Takeaways
- Sutro Biopharma (STRO) shares fell roughly 32% over the last 30 days, from a closing price of $16.35 to around $11.14.
- The decline extends a broader multi-month downtrend, with the stock down more than 50% over the past three months.
- Pressure traces back to August second-quarter 2026 results and an early STRO-004 Phase 1 update that left investors seeking more complete efficacy detail; quarterly revenue fell about 85% year over year.
- The next major readouts are the full STRO-004 (STRIVE-01) study update targeted for the first half of 2027 and third-quarter earnings expected in early November 2026.
- Some analysts view the STRO-004 selloff as an overreaction, though broader sentiment has cooled amid a thinner near-term catalyst calendar.
Sutro Biopharma's Platform and Pipeline Focus
Sutro Biopharma, Inc. is a clinical-stage oncology company based in South San Francisco. It develops next-generation antibody-drug conjugates using its proprietary cell-free protein synthesis platform, XpressCF, along with site-specific conjugation technology. This setup allows the company to fine-tune antibody, linker, and payload elements to enhance drug exposure while aiming to limit side effects and broaden the tumors that can be addressed.
The wholly owned pipeline centers on STRO-004, a Tissue Factor-targeting exatecan ADC now in Phase 1, with STRO-006 (integrin beta-6-targeting) and STRO-227 (PTK7-targeting dual-payload ADC) following behind. Sutro also holds R&D collaborations, including one with Astellas Pharma, and its platform earlier helped support vaccine developer Vaxcyte (PCVX). I checked comparable names in the space using Tickeron’s AI Screener to see how the positioning stacks up.
Recent Stock Price Moves: 30 Days and the Quarter
Over the last 30 days, STRO moved from a closing price of $16.35 down to roughly $11.14, a decline of about 32%. The drop unfolded gradually rather than in one sharp session, with steeper losses appearing in mid-October that took the shares to six-month lows.
The quarterly view shows even more pressure. From levels near $23 in mid-July, the stock has fallen more than 50%. It had traded close to $30 entering July before settling into a pattern of lower highs and lower lows, reflecting a sustained cautious stance that has outweighed the cash position and pipeline updates.
Drivers Behind the Latest 30-Day Decline
The recent slide continues a move that started in mid-August. The key trigger was the August 12 second-quarter 2026 earnings release, which showed revenue of $9.8 million—down roughly 85% year over year—and a net loss of $38.5 million, or $2.33 per share, missing estimates. Revenue comparisons were difficult because the prior-year quarter had included one-time collaboration revenue.
At the same time, Sutro gave an early look at the Phase 1 STRIVE-01 study of STRO-004, noting confirmed and ongoing unconfirmed partial responses in pancreatic, head and neck, and non-small cell lung cancers along with a tolerable safety profile. Investors had hoped for fuller efficacy data, and the lack of detail on response magnitude and durability led to a quick repricing. H.C. Wainwright called the reaction “an overreaction” and kept its Buy rating with a $50 target. I also reviewed the technical setup with Tickeron’s AI Trend Prediction Engine to gauge the momentum shift.
With the next full STRO-004 update not due until the first half of 2027, the stock has had limited near-term catalysts, leaving room for continued selling through September and October.
Context for the Broader Quarterly Weakness
The three-month drop follows a period of optimism that lifted STRO to a 52-week high of $43.85 in May 2026. Earlier gains had been supported by a February 2026 equity raise that extended the cash runway into at least the second quarter of 2028, a round of analyst upgrades, and interest in the ADC platform.
That momentum faded after the August earnings and data release. Limited efficacy detail on STRO-004, paired with the year-over-year revenue drop tied to variable collaboration income, prompted a fresh look at near-term value. Analyst price targets still sit well above current levels—the consensus average around $49.50—yet ratings have eased and the shares have stayed below key moving averages.
Upcoming Catalysts and Considerations
Looking forward, the main items to watch are clinical and financial. The full STRIVE-01 update on STRO-004, expected in the first half of 2027, should give a clearer view of efficacy and durability. Closer in, the start of a Phase 1 trial for STRO-006 and progress toward an IND filing for STRO-227 stand out as pipeline steps.
Financially, third-quarter 2026 results are due in early November, with focus on collaboration revenue trends and cash burn. As of June 30, 2026, Sutro held $164.3 million in cash, cash equivalents, and marketable securities, expected to support operations into at least the second quarter of 2028. Broader market conditions, biotech sentiment, and any rating changes could also affect trading. Execution on clinical programs and future capital needs remain key risks for any company at this stage.
Exploring AI-Powered Trading Approaches
When evaluating volatile names like this, I sometimes turn to Tickeron’s Trending AI Robots page. It highlights top-performing automated bots across strategies, timeframes, and metrics, letting users quickly compare approaches that align with their own risk tolerance and objectives without reviewing the entire catalog. Each bot carries its own methodology and holding profile, so the section helps match tools to personal goals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STRO's RSI Indicator descending into oversold zone
The RSI Indicator for STRO moved into overbought territory on October 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where STRO advanced for three days, in 209 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
STRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STRO as a result. In 74 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for STRO turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 38 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
The 50-day moving average for STRO moved below the 200-day moving average on September 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for STRO entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.732) is normal, around the industry mean (2.988). P/E Ratio (-0.621) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (3.982) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. STRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of new products in protein vaccines and therapeutics
Industry Biotechnology
Advertisement